Aytu Biopharma, Inc AYTU
We take great care to ensure that the data presented and summarized in this overview for AYTU BIOPHARMA, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AYTU
View allLatest Institutional Activity in AYTU
Top Purchases
Top Sells
About AYTU
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Insider Transactions at AYTU
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2024
|
Ryan J Selhorn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+46.83%
|
-
|
|
Nov 06
2024
|
Carl Dockery |
BUY
Grant, award, or other acquisition
|
Direct |
1,500
+12.56%
|
-
|
|
Nov 06
2024
|
John Donofrio Jr. |
BUY
Grant, award, or other acquisition
|
Direct |
1,500
+28.51%
|
-
|
|
Nov 06
2024
|
Abhinav Jain |
BUY
Grant, award, or other acquisition
|
Direct |
1,500
+13.64%
|
-
|
|
Nov 06
2024
|
Vivian H Liu |
BUY
Grant, award, or other acquisition
|
Direct |
1,500
+13.25%
|
-
|
|
Sep 30
2024
|
Greg Pyszczymuka Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
209
+0.89%
|
-
|
|
Jun 30
2024
|
Greg Pyszczymuka Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
208
+0.9%
|
-
|
|
Mar 31
2024
|
Greg Pyszczymuka Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
208
+0.91%
|
-
|
|
Dec 31
2023
|
Greg Pyszczymuka Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
209
+0.92%
|
-
|
|
Sep 30
2023
|
Greg Pyszczymuka Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
208
+0.92%
|
-
|
|
Aug 16
2023
|
Abhinav Jain |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+44.83%
|
-
|
|
Aug 11
2023
|
Vivian H Liu |
BUY
Grant, award, or other acquisition
|
Direct |
1,500
+44.9%
|
-
|
|
Aug 11
2023
|
Abhinav Jain |
BUY
Grant, award, or other acquisition
|
Direct |
1,500
+50.0%
|
-
|
|
Aug 11
2023
|
John Donofrio Jr. |
BUY
Grant, award, or other acquisition
|
Direct |
1,500
+39.87%
|
-
|
|
Aug 11
2023
|
Carl Dockery |
BUY
Grant, award, or other acquisition
|
Direct |
1,500
+14.37%
|
-
|
|
Jun 30
2023
|
Greg Pyszczymuka Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
208
+0.93%
|
-
|
|
Jun 16
2023
|
Greg Pyszczymuka Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+35.36%
|
$12,000
$1.87 P/Share
|
|
Jun 14
2023
|
Joshua R. Disbrow Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
14,000
+16.36%
|
$14,000
$1.86 P/Share
|
|
Apr 25
2023
|
Greg Pyszczymuka Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
833
+7.74%
|
-
|
|
Feb 08
2023
|
Vivian H Liu |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+48.78%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 20K shares |
|---|---|
| Exercise of conversion of derivative security | 834 shares |